Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07081594 · ClinicalTrials.gov registry record

Investigating the Impact of Sex Hormones in Multiple Sclerosis

A clinical trial of Multiple Sclerosis, sponsored by Milap Sandhu.

Active
Registry status
14
Enrollment target
1
Study location

NCT07081594: Active study of Multiple Sclerosis, sponsored by Milap Sandhu.

NCT07081594 is a study of Multiple Sclerosis that is active but no longer recruiting, run by Milap Sandhu. The registered enrollment target is 14 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07081594, a study of Multiple Sclerosis, is active but no longer recruiting, sponsored by Milap Sandhu.

ACTIVE NOT RECRUITING
Registry status
14 participants
Enrollment target
1
Study location

Study Summary

Emerging evidence indicates that females with MS experience worsened symptoms during the luteal phase (post ovulation) of the menstrual cycle when progesterone levels rise and estradiol fluctuate. The rapid hormonal swings may disrupt hypothalamic regulation, leading to an increase in body temperature - a well-established trigger for MS symptom exacerbation. These hormonal changes could also affect neuromuscular function, as estradiol and progesterone receptors are present in the nervous system and skeletal muscles. Three critical aspects of motor rehabilitation are corticospinal excitability, motor learning, and fatigability. Previous research indicates that corticospinal excitability and the capacity to learn fine motor tasks fluctuate across menstrual cycles, indicating hormonal influences on neuroplasticity. However, it remains unclear how these hormonal fluctuations specifically affect corticospinal excitability, motor learning, and motor fatigability in females with MS. Understanding these relationships could significantly improve rehabilitation approaches. For example, pre-menopause females with MS may experience a more optimal state for neuroplasticity during the follicular phase of their cycles, therefore providing a potential window for greater rehabilitation efficacy.

Primary Outcome

Measuring the brain to muscle connection using transcranial magnetic stimulation - a non-invasive way to measure brain activity. Peak to Peak amplitude in mV is recorded

Conditions Studied

Study Locations (1)

Illinois

  • Shirley Ryan AbilityLab - Chicago

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2025-08-28
Est. Completion 2029-03
Milap Sandhu

2 total trials

What the registry record for NCT07081594 still lists

NCT07081594 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT07081594 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT07081594 about?

NCT07081594 is a clinical study titled "Investigating the Impact of Sex Hormones in Multiple Sclerosis". Emerging evidence indicates that females with MS experience worsened symptoms during the luteal phase (post ovulation) of the menstrual cycle when progesterone levels rise and estradiol fluctuate. The rapid hormonal swings may disrupt hypothalamic regulation, leading to an increase in body temperatu...

What is the current status of trial NCT07081594?

This trial is currently active not recruiting. The enrollment target is 14 participants. The study started on 2025-08-28. Estimated completion is 2029-03.

What conditions does trial NCT07081594 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

Who is sponsoring clinical trial NCT07081594?

This trial is sponsored by Milap Sandhu, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07081594 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07081594's enrollment target sits among peer trials

14 291st of 315 higher than 23 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT07081594, the US trial registry maintained by the National Library of Medicine. NCT07081594 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.